Chi Keung Lam1,2, Lei Tian1,2, Nadjet Belbachir1,2, Alexa Wnorowski1,2, Rajani Shrestha1,2, Ning Ma1,2, Tomoya Kitani1,2, June-Wha Rhee1,2, Joseph C Wu1,2,3. 1. From the Stanford Cardiovascular Institute, CA (C.K.L., L.T., N.B., A.W., R.S., N.M., T.K., J.-W.R., J.C.W.). 2. Department of Medicine, Division of Cardiology (C.K.L., L.T., N.B., A.W., R.S., N.M., T.K., J.-W.R., J.C.W.), Stanford University School of Medicine, CA. 3. Deparment of Radiology (J.C.W.), Stanford University School of Medicine, CA.
Abstract
RATIONALE: Calcium channel blockers (CCBs) are an important class of drugs in managing cardiovascular diseases. Patients usually rely on these medications for the remainder of their lives after diagnosis. Although the acute pharmacological actions of CCBs in the hearts are well-defined, little is known about the drug-specific effects on human cardiomyocyte transcriptomes and physiological alterations after long-term exposure. OBJECTIVE: This study aimed to simulate chronic CCB treatment and to examine both the functional and transcriptomic changes in human cardiomyocytes. METHODS AND RESULTS: We differentiated cardiomyocytes and generated engineered heart tissues from 3 human induced pluripotent stem cell lines and exposed them to 4 different CCBs-nifedipine, amlodipine, diltiazem, and verapamil-at their physiological serum concentrations for 2 weeks. Without inducing cell death and damage to myofilament structure, CCBs elicited line-specific inhibition on calcium kinetics and contractility. While all 4 CCBs exerted similar inhibition on calcium kinetics, verapamil applied the strongest inhibition on cardiomyocyte contractile function. By profiling cardiomyocyte transcriptome after CCB treatment, we identified little overlap in their transcriptome signatures. Verapamil is the only inhibitor that reduced the expression of contraction-related genes, such as MYH (myosin heavy chain) and troponin I, consistent with its depressive effects on contractile function. The reduction of these contraction-related genes may also explain the responsiveness of patients with hypertrophic cardiomyopathy to verapamil in managing left ventricular outflow tract obstruction. CONCLUSIONS: This is the first study to identify the transcriptome signatures of different CCBs in human cardiomyocytes. The distinct gene expression patterns suggest that although the 4 inhibitors act on the same target, they may have distinct effects on normal cardiac cell physiology.
RATIONALE: Calcium channel blockers (CCBs) are an important class of drugs in managing cardiovascular diseases. Patients usually rely on these medications for the remainder of their lives after diagnosis. Although the acute pharmacological actions of CCBs in the hearts are well-defined, little is known about the drug-specific effects on human cardiomyocyte transcriptomes and physiological alterations after long-term exposure. OBJECTIVE: This study aimed to simulate chronic CCB treatment and to examine both the functional and transcriptomic changes in human cardiomyocytes. METHODS AND RESULTS: We differentiated cardiomyocytes and generated engineered heart tissues from 3 human induced pluripotent stem cell lines and exposed them to 4 different CCBs-nifedipine, amlodipine, diltiazem, and verapamil-at their physiological serum concentrations for 2 weeks. Without inducing cell death and damage to myofilament structure, CCBs elicited line-specific inhibition on calcium kinetics and contractility. While all 4 CCBs exerted similar inhibition on calcium kinetics, verapamil applied the strongest inhibition on cardiomyocyte contractile function. By profiling cardiomyocyte transcriptome after CCB treatment, we identified little overlap in their transcriptome signatures. Verapamil is the only inhibitor that reduced the expression of contraction-related genes, such as MYH (myosin heavy chain) and troponin I, consistent with its depressive effects on contractile function. The reduction of these contraction-related genes may also explain the responsiveness of patients with hypertrophic cardiomyopathy to verapamil in managing left ventricular outflow tract obstruction. CONCLUSIONS: This is the first study to identify the transcriptome signatures of different CCBs in human cardiomyocytes. The distinct gene expression patterns suggest that although the 4 inhibitors act on the same target, they may have distinct effects on normal cardiac cell physiology.
Authors: Samvit Tandan; Yanggan Wang; Thomas T Wang; Nan Jiang; Duane D Hall; Johannes W Hell; Xiang Luo; Beverly A Rothermel; Joseph A Hill Journal: Circ Res Date: 2009-05-28 Impact factor: 17.367
Authors: Anthony M Pettinato; Dasom Yoo; Jennifer VanOudenhove; Yu-Sheng Chen; Rachel Cohn; Feria A Ladha; Xiulan Yang; Ketan Thakar; Robert Romano; Nicolas Legere; Emily Meredith; Paul Robson; Michael Regnier; Justin L Cotney; Charles E Murry; J Travis Hinson Journal: Cell Rep Date: 2021-05-04 Impact factor: 9.423
Authors: Maksymilian Prondzynski; Marc D Lemoine; Antonia Tl Zech; András Horváth; Vittoria Di Mauro; Jussi T Koivumäki; Nico Kresin; Josefine Busch; Tobias Krause; Elisabeth Krämer; Saskia Schlossarek; Michael Spohn; Felix W Friedrich; Julia Münch; Sandra D Laufer; Charles Redwood; Alexander E Volk; Arne Hansen; Giulia Mearini; Daniele Catalucci; Christian Meyer; Torsten Christ; Monica Patten; Thomas Eschenhagen; Lucie Carrier Journal: EMBO Mol Med Date: 2019-11-03 Impact factor: 14.260
Authors: Suet Nee Chen; Chi Keung Lam; Ying-Wooi Wan; Shanshan Gao; Olfat A Malak; Shane Rui Zhao; Raffaella Lombardi; Amrut V Ambardekar; Michael R Bristow; Joseph Cleveland; Marta Gigli; Gianfranco Sinagra; Sharon Graw; Matthew R G Taylor; Joseph C Wu; Luisa Mestroni Journal: Sci Adv Date: 2022-02-23 Impact factor: 14.136